Labcorp Holdings Inc. (LH)

NYQ – Real vaqt narxi. Valyuta: USD

271.47

+5.13 (1.93%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

272.70

+1.23 (0.45%)

Bozordan keyin: Jun 26, 2026, 7:31 PM EDT

15.06.2026

LH vs. CRL: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

08.06.2026

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

05.06.2026

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

03.06.2026

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

01.06.2026

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.

29.05.2026

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).

28.05.2026

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.

Videolar

No Data

There is no data to display

Press-relizlar

29.05.2026

Labcorp Holdings Inc. (LH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Labcorp Holdings Inc. (LH)

LH vs. CRL: Which Stock Is the Better Value Option?

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Videolar

No Data

Press-relizlar

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

LH vs. CRL: Which Stock Is the Better Value Option?

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Videolar

No Data

Press-relizlar

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Search stocks

Labcorp Holdings Inc. (LH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Labcorp Holdings Inc. (LH)

LH vs. CRL: Which Stock Is the Better Value Option?

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Videolar

No Data

Press-relizlar

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

LH vs. CRL: Which Stock Is the Better Value Option?

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Videolar

No Data

Press-relizlar

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems